Tech Company Financing Transactions

Tarveda Therapeutics Funding Round

Versant Ventures, Flagship Pioneering and NanoDimension participated in a $30 million Series D capital raise for Tarveda Therapeutics. This venture round was announced by the company on 2/4/2017.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

134 Coolidge Avenue
Watertown, MA 02472
USA

Phone

(617) 923-4100

Website

www.tarvedatx.com

Email Address

[email protected]

Overview

Tarveda creates Pentarins that are targeted miniature drug conjugates that remain miniature by design to overcome the challenges that limit the efficacy of larger antibody drug conjugates in use and development today.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Drew Fromkin

        

Chief Medical Officer

Leila Alland

        

VP - Bus. Development

Sudha Kadiyala

        

VP - R & D

Richard Wooster

        

Browse more venture capital transactions:

Prev: 2/4/2017: LendingFront venture capital transaction
Next: 2/4/2017: Authess venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary